We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+31.61%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.19B
AUM Growth
+$204M
Cap. Flow
+$48.2M
Cap. Flow %
4.04%
Top 10 Hldgs %
41.65%
Holding
184
New
58
Increased
50
Reduced
24
Closed
34

Top Buys

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22.4M
2
FOLD
Amicus Therapeutics
FOLD
+$14.4M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$13.8M
4
BLUE
bluebird bio
BLUE
+$11.6M
5
RLYP
RELYPSA INC COM
RLYP
+$11.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.3M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
3
ARWR icon
Arrowhead Research
ARWR
+$18.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.7M
5
HCA icon
HCA Healthcare
HCA
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.07%
2 Financials 0.1%
3 Energy 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
51
Prothena Corp
PRTA
$448M
$5.13M 0.43%
247,336
-52,664
-18% -$1.1M
CBPO
52
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$4.98M 0.42%
74,023
+71,623
+2,984% +$4.44M
NDRM
53
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.91M 0.41%
+350,000
New +$2.77M
ARDX icon
54
Ardelyx
ARDX
$1.24B
$4.83M 0.41%
255,728
+102,651
+67% +$2.38M
XENE icon
55
Xenon Pharmaceuticals
XENE
$6.1B
$4.44M 0.37%
+225,000
New +$3.3M
ABEO icon
56
Abeona Therapeutics
ABEO
$355M
$4.38M 0.37%
+50,000
New +$4.48M
VTRS icon
57
Viatris
VTRS
$20.7B
$4.3M 0.36%
76,210
+26,210
+52% +$1.41M
FPRX
58
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$4.19M 0.35%
155,256
+5,256
+4% +$90.5K
QDEL icon
59
QuidelOrtho
QDEL
$1.13B
$4.12M 0.35%
+142,500
New +$3.86M
TTPH
60
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.97M 0.33%
+5,000
New +$2.69M
AGN
61
DELISTED
Allergan plc
AGN
$3.88M 0.33%
15,088
+88
+0.6% +$22K
THC icon
62
Tenet Healthcare
THC
$22.1B
$3.85M 0.32%
75,913
+8,413
+12% +$440K
ALR
63
DELISTED
Alere Inc
ALR
$3.72M 0.31%
+98,000
New +$3.78M
AVDL
64
DELISTED
Avadel Pharmaceuticals
AVDL
$3.68M 0.31%
644,111
+34,111
+6% +$487K
HCA icon
65
HCA Healthcare
HCA
$90.5B
$3.57M 0.3%
48,639
-181,667
-79% -$12.8M
THOR
66
CALL
DELISTED
THORATEC CORPORATION
THOR
$3.25M 0.27%
+100,000
New +$2.91M
ELGX
67
DELISTED
Endologix Inc
ELGX
$3.21M 0.27%
+21,000
New +$2.62M
DBVT
68
DBV Technologies
DBVT
$814M
$3.05M 0.26%
+11,262
New +$2.9M
PFNX
69
DELISTED
Pfenex Inc.
PFNX
$2.96M 0.25%
404,665
+4,665
+1% +$35.3K
VBLX
70
DELISTED
VASCULAR BIOGENICS LTD ORD SHS (ISR)
VBLX
$2.96M 0.25%
+500,000
New +$2.96M
DSCI
71
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2.92M 0.24%
313,583
+97,774
+45% +$850K
QURE icon
72
uniQure
QURE
$2.76B
$2.9M 0.24%
+195,856
New +$2.4M
TARA icon
73
Protara Therapeutics
TARA
$213M
$2.86M 0.24%
+6,875
New +$2.77M
KERX
74
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.83M 0.24%
200,000
– –
DERM
75
DELISTED
Dermira, Inc.
DERM
$2.75M 0.23%
+152,000
New +$2.54M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Perceptive Advisors held 184 positions worth $1.19B, up 21% from $988M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Perceptive Advisors deployed $48.2M of net new capital in Q4 2014, opening 58 new positions and adding to 50 existing holdings. Its largest new stake was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was Celgene Corp, an estimated $24.3M trimmed.

  • Perceptive Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q4 2014, an estimated $14.4M increase.
  • Perceptive Advisors's biggest Q4 2014 reduction was Celgene Corp, cutting an estimated $24.3M.
  • Perceptive Advisors fully exited Arrowhead Research in Q4 2014, selling an estimated $18.4M.
  • Perceptive Advisors's ten largest holdings make up 42% of its $1.19B portfolio in Q4 2014.
  • Perceptive Advisors opened 58 new positions and closed 34 in Q4 2014.
  • Perceptive Advisors's portfolio value rose 21% quarter-over-quarter to $1.19B.

Based on Perceptive Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.